羟基磷灰石作为药物载体在骨修复领域的研究进展  

Research Progress of Hydroxyapatite as Drug Carrier in Bone Repair

作　　者：潘依雯 倪昕晔 王车礼[1] PAN Yiwen;NI Xinye;WANG Cheli(Changzhou University,Changzhou Jiangsu 213000,China;Changzhou Second People's Hospital,Nanjing Medical University,Changzhou Jiangsu 213003,China)

机构地区：[1]常州大学,江苏常州213000 [2]南京医科大学附属常州第二人民医院,江苏常州213003

出　　处：《药品评价》2022年第17期1079-1083,共5页Drug Evaluation

基　　金：国家自然科学基金面上项目(81871756)。

摘　　要：羟基磷灰石具有良好的抗压强度和生物相容性,是目前骨组织工程中运用最广泛的生物材料,但是单一的材料往往作用有限。因此利用其特殊的孔隙结构作为药物载体和抗生素、抗骨质疏松药物、抗肿瘤药物、生长因子等结合在骨损伤修复领域发挥更大优势,如降低药物细胞毒性,延长药物作用时间等。本文就多种药物与羟基磷灰石结合的制备方法、优缺点等进行综述,旨为羟基磷灰石载药复合支架修复骨损伤提供理论依据。Hydroxyapatite has good compressive strength and biocompatibility.It is the most widely used biomaterial in bone tissue engineering,but a single material often has limited effect.Therefore,the use of its special pore structure as a drug carrier,combined with antibiotics,anti osteoporosis drugs,anti-tumor drugs and growth factors,plays a greater advantage in the field of bone injury repair,such as reducing drug cytotoxicity and prolonging drug action time.This paper lists a variety of drugs,and reviews the preparation methods,advantages and disadvantages of their combination with hydroxyapatite.The aim is to provide a theoretical basis for repairing bone injury with hydroxyapatite drug-loaded composite scaffold.

关 键 词：羟基磷灰石类 假体和植入物 骨再生 药物载体 组织支架 骨损伤修复 复合支架 

分 类 号：R318.08[医药卫生—生物医学工程]